SCIENTIFIC PUBLICATIONS

The links on this page are not affiliated with Mitsubishi Tanabe Pharma America, Inc. (MTPA). Links to sites outside of MTPA are provided as a resource to the viewer. MTPA accepts no responsibility for the content of linked sites. Some links may direct to third-party websites that require a subscription to access publications.

  • Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19)
    —Shefner J, Heiman‐Patterson T, Pioro EP, et al. Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19). Muscle & Nerve. 2019;61(2):218-221. doi:10.1002/mus.26740.
    View article
  • Post-hoc analysis of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis
    —Palumbo JM, Hubble J, Apple S, et al. Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2019;20(5-6):421-431. doi:10.1080/21678421.2019.1599955.
    View article
  • A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis
    —The Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2017;18(sup1):11-19. doi:10.1080/21678421.2017.1363780.
    View article
  • Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
    —The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 2017;16(7):505-512. doi: 1016/S1474-4422(17)30115-1.
    View article
  • Mitsubishi Tanabe Pharma America presented real-world experience outcomes during IV edaravone treatment at the virtual 31st International Symposium on ALS/MND
    —Hagan M, Ciepielewska M, Harrison A, et al. Treatment Persistence Among Amyotrophic Lateral Sclerosis Patients Receiving Intravenous Edaravone: Results From a National Infusion Center. Poster presented at 31st International Symposium on ALS/MND; December 9-11, 2020.
    View article
  • Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
    —Al-Chalabi A, Chiò A, Merrill C, et al. Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19 [published online ahead of print October 27, 2020]. J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2020-323271.
    View article

The studies referenced herein are provided for general information only and are not intended as statements about the safety or efficacy of any product.